[mkdf_section_title position=”” show_separator=”yes” separator_position=”center” title_tag=”” disable_break_words=”no” title=”Pubblicazioni 2016″ holder_padding=”13px”]
Italian daily platelet transfusion practice for haematological patients undergoing high dose chemotherapy with or without stem cell transplantation: a survey by the GIMEMA Haemostasis and Thrombosis Working Party.
Tagariello G, Castaman G, Falanga A, Santoro R, Napolitano M, Storti S, Veneri D, Basso M, Candiotto L, Tassinari C, Federici AB, De Stefano V; GIMEMA Haemostasis and Thrombosis working party.
Blood Transfus. 2016 Nov;14(6):521-526.
Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors.
Falanga A, Marchetti M, Massi D, Merelli B, Verzeroli C, Russo L, Rulli E, Tondini C, Legramandi L, Nassini R, Scatena C, De Logu F, Cattaneo L, Mandalà M.
J Am Acad Dermatol. 2016;74(6):1254-1256.e4.
A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality.
Kuderer NM, Culakova E, Lyman GH, Francis C, Falanga A, Khorana AA.
Oncologist. 2016;21(7):861-7.
Molecular biomarkers of thrombosis in myeloproliferative neoplasms.
Barbui T, Falanga A.
Thromb Res. 2016;140 Suppl 1:S71-5.
Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study.
Falanga A, Santoro A, Labianca R, De Braud F, Gasparini G, D’Alessio A, Barni S, Iacoviello L; HYPERCAN Study Group.
Thromb Res. 2016;140 Suppl 1:S55-9.